Aldeyra Therapeutics, Inc.
At a glance
Most recent filing on November 13, 2026 — an open-market purchase by Alfieri Michael on Nov 11, 2026.
Since November 13, 2026: 2 open-market purchases and 0 open-market sales.
We hold 2 Form 4 lines, going back to November 13, 2026.
Insider trades
How to read a Form 4All 2 shown
- Alfieri Michael Principal Financial Officer$6,500Open-market buy
- DOUGLAS RICHARD Director$128,900Open-market buy
CEO pay
What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.
Todd C. Brady, M.D., Ph.D, fiscal year ended Dec 31, 2025: total $4,704,379, actually paid $4,290,265. First reported Apr 27, 2026.
Earlier fiscal years are part of the subscription.